In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and...

Lotte Biologics, part of South Korean conglomerate Lotte, has detailed expansions plans for the business as it embarks on a path to become a top 10 CDMO by 2030.

What does 2022 hold for the biopharma industry? Which companies can play at the forefront in terms of products as well as business? Covid-19 will continue to be a...

Bristol-Myers Squibb (BMS) is suing AstraZeneca Pharmaceuticals, alleging that the Anglo-Swedish drugmaker’ Imfinzi to treat lung and bladder cancer infringes several...

WuXi STA, CDMO subsidiary of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from US pharma Bristol Myers...

US drugmaker Bristol Myers Squibb has signed an exclusive license agreement for Agenus’ proprietary bispecific antibody program AGEN1777, that blocks TIGIT and a second...

US drugmaker Bristol Myers Squibb has chosen Leiden in the Netherlands for a new cell therapy manufacturing site in Europe as it continues to expand and develop...

China contract development and manufacturing organization (CDMO) WuXi STA has agreed to buy Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland, for an...